CIP2A is associated with human breast cancer aggressivity

Clinical Cancer Research

Volumn 15, Issue 16, 2009, Pages 5092-5100

  Côme, Christophe ^a   Laine, Anni ^a   Chanrion, Maïa ^c   Edgren, Henrik ^b,d   Mattila, Elina ^b   Liu, Xiaoling ^e   Jonkers, Jos ^e   Ivaska, Johanna ^b   Isola, Jorma ^f   Darbon, Jean Marie ^c   Kallioniemi, Olli ^b,d   Thézenas, Simon ^c   Westermarck, Jukka ^a,g  

^a UNIVERSITY OF TURKU   (Finland)

^b VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^c INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^d UNIVERSITY OF HELSINKI   (Finland)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY OF TAMPERE   (Finland)

^g Finnish Cancer Institute   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MESSENGER RNA; MYC PROTEIN; ONCOPROTEIN; ONCOPROTEIN CIP2A; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AUTOANTIGENS; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LINKAGE (GENETICS); MEMBRANE PROTEINS; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69349102025     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3283     Document Type: Article

References (22)

1. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007;117:3155-3163
2. Zhao JJ, Roberts TM, Hahn WC. Functional genetics and experimental models of human cancer. Trends Mol Med 2004;10:344-350 (Pubitemid 38881524)
3. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004;6: 171-183 (Pubitemid 39485689)
4. Sablina AA, Chen W, Arroyo JD, et al. The tumor suppressor PP2A Aβ regulates the RalA GTPase. Cell 2007;129:969-982 (Pubitemid 46813152)
5. Calin GA, di Iasio MG, Caprini E, et al. Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000;19:1191-1195 (Pubitemid 30157549)
6. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008;7:592-596
7. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-318 (Pubitemid 38584820)
8. Malempati S, Tibbitts D, Cunningham M, et al. Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia 2006; 20:1572-1581 (Pubitemid 44264101)
9. Chrzan P, Skokowski J, Karmolinski A, Pawelczyk T. Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin Biochem 2001;34:557-562 (Pubitemid 34014849)
10. Naidu R, Wahab NA, Yadav M, Kutty MK. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 2002;9: 189-196
11. Junttila MR, Puustinen P, Niemela M, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007;130:51-62. (Pubitemid 47039258)
12. Li W, Ge Z, Liu C, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 2008;14: 3722-3728
13. Chanrion M, Fontaine H, Rodriguez C, et al. A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. BMC Cancer 2007;7:39.
14. Come C, Magnino F, Bibeau F, et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006;12: 5395-5402 (Pubitemid 44497253)
15. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002;21:5006-5015
16. Laakso M, Tanner M, Nilsson J, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006;12:4185-4191
17. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-13555 (Pubitemid 41420886)
18. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-425 (Pubitemid 34326692)
19. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 2007;104:12111-12116 (Pubitemid 47185638)
20. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83:1688-1695
21. Tavassoli M, Quirke P, Farzaneh F, Lock NJ, Mayne LV, Kirkham N. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br J Cancer 1989;60:505-510 (Pubitemid 19251440)
22. Popov N, Wanzel M, Madiredjo M, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007;9:765-774 (Pubitemid 47019463)